Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Harith Rajagopalan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 100
- Beta
- 2.33
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -13.07
Financials
Revenue
$0.00-100.0%Net Income
$-25.54MEBITDA
$-24.98MFree Cash Flow
$-15.90MEPS (diluted)
$-0.16Shares Outstanding (diluted)
158.65M+8559.3%Operating Expenses
$19.10MCash & Debt
$47.14MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-140.95M | $-0.92 |
| 2024 | $93.0K | $-68.69M | $-1.62 |
| 2023 | $120.0K | $-77.09M | $-1.98 |
| 2022 | $0.00 | $-46.45M | $-1.34 |
| 2021 | $0.00 | $-38.73M | $-1.12 |
| 2020 | $0.00 | $-30.48M | $-0.86 |
| 2019 | $0.00 | $-30.59M | $-0.64 |
Valuation
GUTShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+66.67%Social Signal Score
Mentions (11)
- Newsglobenewswire.com·7d ago·Neutral
Portnoy Law Firm Announces Class Action on Behalf of Fractyl Health, Inc. Investors LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Fractyl Health, Inc., (“Fractyl” or the "Company") (NASDAQ: GUTS) investors of a class action on behalf of investors that bought securities between January 13, 2025 - January 29, 2026, inclusive (the “Class Period”).
View source ↗ - Newsseekingalpha.com·21d ago·Positive
Fractyl Health, Inc. (GUTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Fractyl Health, Inc. (GUTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
Fractyl Health to Participate in Upcoming September Investor Conferences BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D.
View source ↗ - Newsprnewswire.com·32d ago·Negative
Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit BENSALEM, Pa., Sept. 3, 2026 /PRNewswire/ -- The Law Offices of Howard G.
View source ↗ - Newsseekingalpha.com·34d ago·Positive
Fractyl Health, Inc. (GUTS) Discusses Commercialization Strategy for Investigational Post-GLP-1 Procedural Therapy Transcript Fractyl Health, Inc. (GUTS) Discusses Commercialization Strategy for Investigational Post-GLP-1 Procedural Therapy Transcript
View source ↗ - Newsbusinesswire.com·41d ago·Negative
Securities Fraud Investigation Into Fractyl Health, Inc. (GUTS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) on behalf of investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON FRACTYL HEALTH, INC. (GUTS), CLICK HERE TO INQUIRE A…
View source ↗ - Newsgurufocus.com·45d ago·Neutral
Stockholder Alert: Robbins LLP Informs Investors of the Fractyl Health, Inc. Class Action Shareholder rights law firm [url="]Robbins LLP[/url] informs investors that a class action was filed on behalf of all persons and entities who purchased or othe
View source ↗ - Newsbusinesswire.com·45d ago·Negative
Stockholder Alert: Robbins LLP Informs Investors of the Fractyl Health, Inc. Class Action SAN DIEGO--(BUSINESS WIRE)---- $GUTS #Fractyl--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ: GUTS) securities between January 13, 2025 and January 29, 2026 (the "Class Period"). Fractyl is a metabolic therapeutics company that develops therapies for the treatment …
View source ↗ - Newsmarketbeat.com·53d ago·Neutral
Fractyl Health Eyes Q4 Revita Data, Launches Rejuva Gene Therapy Trial Fractyl Health NASDAQ: GUTS is advancing two one-time treatment approaches intended to provide durable benefits for obesity, type 2 diabetes and related metabolic diseases, Chief Executive Officer Harith Rajagopalan said during a Canaccord discussion.
View source ↗ - Newsseekingalpha.com·56d ago·Positive
Fractyl Health, Inc. (GUTS) Q2 2026 Earnings Call Transcript Fractyl Health, Inc. (GUTS) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·56d ago·Negative
Fractyl Health Q2 Earnings Call Highlights Fractyl Health NASDAQ: GUTS said its Revita endoscopic procedure showed durable weight-maintenance results one year after patients discontinued GLP-1 therapy, while the company reaffirmed plans to report pivotal trial data in early fourth-quarter 2026 and pursue a potential FDA De Novo submission later in the year.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.13 per share
Typical surprise -18.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.12 vs $-0.14beat
- Tue, May 12$0.06 vs $-0.17beat
- Tue, Mar 24$-0.29 vs $-0.19miss
- Wed, Nov 12$-0.71 vs $-0.34miss
- Tue, Aug 12$-0.53 vs $-0.37miss
- Tue, May 13$-0.49 vs $-0.49beat
Estimates and results for GUTS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GUTS officers and directors.
- Bought
- $291k
- Sold
- $874k
12 trades
7 trades
- Bradley Williambought
- Royan Ajaybought
- Bradley Williambought
- Sheffield Ianbought
- Rajagopalan Harithbought
- Smith Weber Larabought
- Rajagopalan Harithbought
- Royan Ajaybought
81 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in GUTS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.